Literature DB >> 29134554

Ex vivo rabbit cornea diffusion studies with a soluble insert of moxifloxacin.

María Sebastián-Morelló1, María Aracely Calatayud-Pascual1, Vicent Rodilla1, Cristina Balaguer-Fernández1, Alicia López-Castellano2.   

Abstract

The objective of this research was to develop and evaluate an ocular insert for the controlled drug delivery of moxifloxacin which could perhaps be used in the treatment of corneal keratitis or even bacterial endophthalmitis. We have evaluated the ex vivo ocular diffusion of moxifloxacin through rabbit cornea, both fresh and preserved under different conditions. Histological studies were also carried out. Subsequently, drug matrix inserts were prepared using bioadhesive polymers. The inserts were evaluated for their physicochemical parameters. Ophthalmic ex vivo permeation of moxifloxacin was carried out with the most promising insert. The formulate insert was thin and provided higher ocular diffusion than commercial formulations. Ocular diffusion studies revealed significant differences between fresh and frozen corneas. Histological examinations also showed differences in the thickness of stroma between fresh and frozen corneas. The ophthalmic insert we have developed allows a larger quantity of moxifloxacin to permeate through the cornea than existing commercial formulations of the drug. Ocular delivery of moxifloxacin with this insert could be a new approach for the treatment of eye diseases.

Entities:  

Keywords:  Bacterial endophthalmitis; Drug delivery; Insert; Moxifloxacin; Ophthalmic

Mesh:

Substances:

Year:  2018        PMID: 29134554     DOI: 10.1007/s13346-017-0443-y

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  35 in total

1.  Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride.

Authors:  A S Mundada; B K Shrikhande
Journal:  Drug Dev Ind Pharm       Date:  2006-04       Impact factor: 3.225

2.  Passive asymmetric transport of hesperetin across isolated rabbit cornea.

Authors:  Ramesh Srirangam; Soumyajit Majumdar
Journal:  Int J Pharm       Date:  2010-05-09       Impact factor: 5.875

3.  Development and evaluation of occlusive systems employing polyvinyl alcohol for transdermal delivery of sumatriptan succinate.

Authors:  C Balaguer-Fernández; C Padula; A Femenía-Font; V Merino; P Santi; A López-Castellano
Journal:  Drug Deliv       Date:  2010-02       Impact factor: 6.419

4.  Comparative permeability of human and rabbit corneas to cyclosporin and tritiated water.

Authors:  Pieter Van Der Bijl; A H Engelbrecht; Armorél D Van Eyk; David Meyer
Journal:  J Ocul Pharmacol Ther       Date:  2002-10       Impact factor: 2.671

5.  Donor corneae for preservation. A modified dissection technique.

Authors:  V Kalevar
Journal:  Br J Ophthalmol       Date:  1968-09       Impact factor: 4.638

6.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

7.  Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.

Authors:  Eric D Donnenfeld; Timothy L Comstock; Joel W Proksch
Journal:  J Cataract Refract Surg       Date:  2011-06       Impact factor: 3.351

8.  Vitreous and aqueous penetration of orally administered moxifloxacin in humans.

Authors:  Seenu M Hariprasad; Gaurav K Shah; William F Mieler; Leonard Feiner; Kevin J Blinder; Nancy M Holekamp; Hua Gao; Randall A Prince
Journal:  Arch Ophthalmol       Date:  2006-02

9.  Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study.

Authors:  Nimmagadda Srinivas; Lakshmi Narasu; B Prabha Shankar; Ramesh Mullangi
Journal:  Biomed Chromatogr       Date:  2008-11       Impact factor: 1.902

Review 10.  Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: a large-scale review.

Authors:  Sydney L Tyson; Robert Bailey; Janika S Roman; Tingting Zhan; Lisa A Hark; Julia A Haller
Journal:  Curr Opin Ophthalmol       Date:  2017-01       Impact factor: 3.761

View more
  5 in total

1.  Design of Topical Moxifloxacin Mucoadhesive Nanoemulsion for the Management of Ocular Bacterial Infections.

Authors:  Ahmed Adel Ali Youssef; Ruchi Thakkar; Samir Senapati; Poorva H Joshi; Narendar Dudhipala; Soumyajit Majumdar
Journal:  Pharmaceutics       Date:  2022-06-12       Impact factor: 6.525

2.  Micelles of Progesterone for Topical Eye Administration: Interspecies and Intertissues Differences in Ex Vivo Ocular Permeability.

Authors:  Adrián M Alambiaga-Caravaca; María Aracely Calatayud-Pascual; Vicent Rodilla; Angel Concheiro; Alicia López-Castellano; Carmen Alvarez-Lorenzo
Journal:  Pharmaceutics       Date:  2020-07-26       Impact factor: 6.321

3.  Improved Ocular Bioavailability of Moxifloxacin HCl using PLGA Nanoparticles: Fabrication, Characterization, In-vitro and In-vivo Evaluation.

Authors:  Fahim Ullah Khan; Fazli Nasir; Zafar Iqbal; Steven Neau; Ismail Khan; Mohammad Hassan; Muhammad Iqbal; Aman Ullah; Sumaira Irum Khan; Mirina Sakhi
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

Review 4.  The Use of Polymer Blends in the Treatment of Ocular Diseases.

Authors:  Raquel Gregorio Arribada; Francine Behar-Cohen; Andre Luis Branco de Barros; Armando Silva-Cunha
Journal:  Pharmaceutics       Date:  2022-07-07       Impact factor: 6.525

5.  Ex-Vivo Trans-Corneal and Trans-Scleral Diffusion Studies with Ocular Formulations of Glutathione as an Antioxidant Treatment for Ocular Diseases.

Authors:  María Sebastián-Morelló; Adrián M Alambiaga-Caravaca; María Aracely Calatayud-Pascual; Vicent Rodilla; Cristina Balaguer-Fernández; María Miranda; Alicia López-Castellano
Journal:  Pharmaceutics       Date:  2020-09-10       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.